Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension trial of arimoclomol in ALS (ORARIALS-01 extension)
2019-000374-39Phase 3Unknown
- Sponsor
- Orphazyme A/S
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of arimoclomol in amyotrophic lateral sclerosis (ALS), sponsored by Orphazyme A/S. Primary endpoint: Incidence and severity of TEAEs over a treatment period of 76 weeks. Status: unknown.
02
Drugs
arimoclomol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2019-000374-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000374-39.